Table 1.
Patients’ baseline characteristics depending on COVID-19 severity.
| Parameters | Moderate (n = 173) | Severe (n = 128) | p |
|---|---|---|---|
| Age, years, Me + IQR [25; 75] | 59 [51; 68] | 66 [58; 75] | <0.001 |
| Gender, female, n (%) | 89 (51.4) | 61 (47.7) | 0.52 |
| Days from symptom onset to hospitalization, days, Me + IQR [25; 75] | 8 [6; 11] | 8 [6; 11] | 0.92 |
| Bed days, days, Me + IQR [25; 75] | 15 [13; 20] | 19 [13; 27] | 0.003 |
| CT lung involvement, %, Me + IQR [25; 75] | 30 [20; 45] | 68 [55; 76] | <0.001 |
| BMI, kg/m2, Me + IQR [25; 75] | 29 [26; 32] | 29 [25; 34] | 0.66 |
| Obesity, n (%) | 69 (39.9) | 55 (43.0) | 0.048 |
| DM type 2, n (%) | 47 (27.2) | 55 (43.0) | 0.004 |
| AH, n (%) | 123 (71.1) | 111 (86.7) | 0.001 |
| IHD, n (%) | 37 (21.4) | 66 (51.6) | <0.001 |
| CKD, n (%) | 13 (7.5) | 21 (16.4) | 0.017 |
| Neutrophils, ×109/L, Me + IQR [25; 75] | 4.8 [3.4; 7.3] | 5.7 [3.4; 8.1] | 0.16 |
| Lymphocytes, ×109/L, Me + IQR [25; 75] | 1.2 [0.8; 1.5] | 0.9 [0.7; 1.3] | 0.002 |
| NLR, Me + IQR [25; 75] | 4.2 [2.7; 7.1] | 5.7 [2.9; 10.1] | 0.007 |
| 25(OH)D, ng/mL, Me + IQR [25; 75] | 18.9 [10.2; 33.3] | 14.8 [8.3; 21.3] | 0.001 |
| Plasma glucose, mmol/L, Me + IQR [25; 75] | 6.5 [5.9; 8.0] | 7.7 [6.5; 9.3] | <0.001 |
| CRP, mg/L, Me + IQR [25; 75] | 39.6 [20.7; 91.4] | 93.1 [53.4; 190.7] | <0.001 |
| Ferritin, ng/mL, Me + IQR [25; 75] | 488 [234; 825] | 776 [381; 1296] | <0.001 |
| LDH, u/L, Me + IQR [25; 75] | 341 [267; 482] | 541 [399; 726] | <0.001 |
| D-dimer, µg/mL FEU, Me + IQR [25; 75] | 0.3 [0.2; 0.5] | 0.6 [0.4; 0.9] | <0.001 |
| Creatinine, mcmol/L, Me + IQR [25; 75] | 68 [58; 77] | 68 [51; 83] | 0.74 |
CT—computer tomography; BMI—body mass index; DM—diabetes mellitus; AH—arterial hypertension; IHD—ischemic heart disease; CKD—chronic kidney disease; NLR—neutrophils/lymphocytes ratio; 25(OH)D—25-hydroxyvitamin D; CRP—C-reactive protein; LDH—lactate dehydrogenase; Me—median; and IQR—interquartile range.